Global PVA Drugs Market 2014-2018
出 版 商：Infiniti Research
出版日期：2014/04/25
頁 數：58頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 3,500 (Multi-User License)
USD 10,000 (Global-User License)
USD 3,500 (Multi-User License)
USD 10,000 (Global-User License)
About PVA Drugs
Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA.
TechNavio's analysts forecast the Global PVA Drugs market will grow at a CAGR of 7.1 percent over the period 2013-2018.
Covered in this Report
The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA.
TechNavio's report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ EMEA
‧ APAC
Key Vendors
‧ Actavis plc
‧ Novo Nordisk A/S
‧ Pfizer Inc.
‧ Shionogi & Co. Ltd.
Other Prominent Vendors
‧ ANI Pharmaceuticals Inc.
‧ Bionovo Inc.
‧ EndoCeutics Inc.
‧ QuatRx Pharmaceutical Co.
‧ PeP-Tonic Medical AB
‧ Teva Pharmaceutical Industries Ltd.
‧ Therapeutics MD Inc.
‧ Upsher-Smith Laboratories Inc.
Market Driver
‧ Significant Unmet Need.
‧ For a full, detailed list, view our report.
Market Challenge
‧ Increasing Number of Patent Expirations.
‧ For a full, detailed list, view our report.
Market Trend
‧ Increase in Awareness of PVA.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA.
TechNavio's analysts forecast the Global PVA Drugs market will grow at a CAGR of 7.1 percent over the period 2013-2018.
Covered in this Report
The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA.
TechNavio's report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
‧ Americas
‧ EMEA
‧ APAC
Key Vendors
‧ Actavis plc
‧ Novo Nordisk A/S
‧ Pfizer Inc.
‧ Shionogi & Co. Ltd.
Other Prominent Vendors
‧ ANI Pharmaceuticals Inc.
‧ Bionovo Inc.
‧ EndoCeutics Inc.
‧ QuatRx Pharmaceutical Co.
‧ PeP-Tonic Medical AB
‧ Teva Pharmaceutical Industries Ltd.
‧ Therapeutics MD Inc.
‧ Upsher-Smith Laboratories Inc.
Market Driver
‧ Significant Unmet Need.
‧ For a full, detailed list, view our report.
Market Challenge
‧ Increasing Number of Patent Expirations.
‧ For a full, detailed list, view our report.
Market Trend
‧ Increase in Awareness of PVA.
‧ For a full, detailed list, view our report.
Key Questions Answered in this Report
‧ What will the market size be in 2018 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.1.1 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 PVA Drugs Market in the US
06.3.1 Market Size and Forecast
06.4 PVA Drugs Market in Europe
06.4.1 Market Size and Forecast
06.5 Five Forces Analysis
07. Competitive Analysis of Marketed Products
08. Pipeline Snapshot
09. Rate of Incidence and Prevalence
10. Market Segmentation by Types
10.1 Topical Estrogen
10.1.1 Vaginal Cream
10.1.2 Vaginal Tablet
10.1.3 Vaginal Ring
10.2 Systemic Estrogen
10.2.1 Oral Estradiol
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Pfizer Inc.
20.1.1 Business Overview
20.1.2 Business Segmentation
20.1.3 Key Information
20.1.4 SWOT Analysis
20.2 Shionogi & Co. Ltd.
20.2.1 Business Overview
20.2.2 Key Information
20.2.3 SWOT Analysis
20.3 Novo Nordisk A/S
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Key Information
20.3.4 SWOT Analysis
20.4 Actavis plc
20.4.1 Business Overview
20.4.2 Business Segmentation
20.4.3 Key Information
20.4.4 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global PVA Drugs Market 2013-2018 (US$ billion)
Exhibit 3: PVA Drugs Market in the US 2013-2018 (US$ billion)
Exhibit 4: PVA Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 5: Global PVA Drugs Market Segmentation by Route of Administration
Exhibit 6: Global PVA Drugs Market by Geographical Segmentation 2013
Exhibit 7: Business Segmentation of Pfizer Inc.
Exhibit 8: Business Segmentation of Novo Nordisk A/S
Exhibit 9: Business Segmentation of Actavis plc
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.1.1 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 PVA Drugs Market in the US
06.3.1 Market Size and Forecast
06.4 PVA Drugs Market in Europe
06.4.1 Market Size and Forecast
06.5 Five Forces Analysis
07. Competitive Analysis of Marketed Products
08. Pipeline Snapshot
09. Rate of Incidence and Prevalence
10. Market Segmentation by Types
10.1 Topical Estrogen
10.1.1 Vaginal Cream
10.1.2 Vaginal Tablet
10.1.3 Vaginal Ring
10.2 Systemic Estrogen
10.2.1 Oral Estradiol
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2013
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Pfizer Inc.
20.1.1 Business Overview
20.1.2 Business Segmentation
20.1.3 Key Information
20.1.4 SWOT Analysis
20.2 Shionogi & Co. Ltd.
20.2.1 Business Overview
20.2.2 Key Information
20.2.3 SWOT Analysis
20.3 Novo Nordisk A/S
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Key Information
20.3.4 SWOT Analysis
20.4 Actavis plc
20.4.1 Business Overview
20.4.2 Business Segmentation
20.4.3 Key Information
20.4.4 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global PVA Drugs Market 2013-2018 (US$ billion)
Exhibit 3: PVA Drugs Market in the US 2013-2018 (US$ billion)
Exhibit 4: PVA Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 5: Global PVA Drugs Market Segmentation by Route of Administration
Exhibit 6: Global PVA Drugs Market by Geographical Segmentation 2013
Exhibit 7: Business Segmentation of Pfizer Inc.
Exhibit 8: Business Segmentation of Novo Nordisk A/S
Exhibit 9: Business Segmentation of Actavis plc
